LIBRETTO-001: Final analysis showed durable responses with selpercatinib in patients with RET fusion-positive NSCLC

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

JTO Clin Res Rep

Lucibello F, Gounant V, Aldea M, Duruisseaux M, Perol M, Chouaid C, Bennouna J, Fallet V, Renault A, Guisier F, Giroux-Leprieur E, Wislez M, Toffart AC, Mazieres J, Basse C, Hegarat N, Carton M, Girard N

doi: 10.1016/j.jtocrr.2024.100743

Lung, Respiratory and Thoracic Cancer

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

J Thorac Oncol

Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT

doi: 10.1016/j.jtho.2024.09.1443

Lung, Respiratory and Thoracic Cancer

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer

J Clin Oncol

Pérol M, Solomon BJ, Goto K, Park K, Nadal E, Bria E, Martin C, Bar J, Williams JN, Puri T, Li J, Uh MK, Lin BK, Zhou C

doi: 10.1200/JCO.24.00724

Lung, Respiratory and Thoracic Cancer

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Eur J Cancer

Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.ejca.2024.113600

ASCO 2024

Breast Cancer

Pooled analysis of DESTINY-Breast01, -02 and -03: Patients with objective response to T-DXd achieved prolonged survival

WCLC 2024

Lung, Respiratory and Thoracic Cancer

TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC

ASCO 2024

Genitourinary Cancer

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

EHA 2024

Multiple Myeloma (MM)

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

Related content

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Pooled analysis of DESTINY-Breast01, -02 and -03: Patients with objective response to T-DXd achieved prolonged survival

TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC